Imagine Healthcare Announces Expanded Access To Spravato - Now Available Without The Need For An Oral Antidepressant
( MENAFN - EIN Presswire) Spravato® (esketamine) has been approved for use as a standalone treatment for depression, without the requirement of an accompanying antidepressant. Rachel Norris, MD ...
Live Science on MSN7h
FDA approves 'ketamine' nasal spray for depression — here's everything you need to know
A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with ...
Top Research Reports for NVIDIA, Johnson & Johnson and T-Mobile
Today's Research Daily features new research reports on 16 major stocks, including NVIDIA Corporation (NVDA), Johnson & ...
Ketamine-derived nasal spray treating Phoenix patients with severe depression
PHOENIX (AZFamily) — A ketamine-derived nasal spray is now available for the millions of Americans living with severe depression. The hallucinogenic drug is an option when traditional treatment isn’t ...
Canaccord cuts Intra-Cellular stock rating, raises target to $132
Canaccord Genuity analysts downgraded Intra-Cellular Therapies (NASDAQ:ITCI) stock from Buy to Hold, adjusting the price target to $132 from the previous $119. The revision follows the recent ...
KADN10h
Covering Your Health: New depression drug offers hope
For those with major depression, there is a new treatment option - one that offers hope when patients are not responding to ...